DossierENTITY

Biotech M&A

Coverage of Biotech M&A in the Nexus archive.

Earliest in view: Jun 4 · 05:45 UTCMost recent: Jun 4 · 05:45 UTC

Co-mentioned in this coverage

Recent coverage

BUSINESSJun 4 · 05:45 UTCCNBC TOP
‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid
Biotech mergers and acquisitions in 2026 are experiencing a strong start, driven by patent cliffs, rising public market confidence, and pharmaceutical companies seeking to enhance their drug pipelines.